Objective: The aim of this study was to identify clinicopathological variables associated with the clinical outcomes of patients with lymph node metastasis-positive urothelial bladder carcinoma after radical cystectomy. Methods: Forty-six patients who underwent radical cystectomy without preoperative chemotherapy and had histologically proven nodal metastasis were included in the study. The status of lymph nodes and primary lesion was analyzed in terms of disease-specific survival and recurrence-free survival.
INTRODUCTION
Radical cystectomy with pelvic lymph node (LN) dissection is a gold standard treatment for muscle-invasive bladder cancer (1); 18 -28% of the patients who undergo radical cystectomy are found to have LN metastases upon histological examination of their surgically resected specimens (1) . The 5-year overall survival and recurrence-free survival (RFS) of patients with LN metastases (pN1 -3) are reported to be 25 -31 and 20-35%, respectively (2) , and their clinical outcomes are highly variable.
Several clinicopathological factors that can further stratify the risk of recurrence and death in node-positive patients have been identified: the number of LNs involved with the tumor (3 -7) , the number of LNs removed (5, 7) , the ratio (percentage) of the number of involved nodes divided by the total number of nodes removed (LN density) (4,5,8 -11) , primary pathological stage (pT) (3 -5) , extranodal invasion (ENI) of LN metastases (12 -14) and the use of adjuvant chemotherapy (6, 15) .
Among these variables, the significance of the total number of LNs involved with the tumor and LN density have been well examined and are becoming accepted as prognostic variables, although the use of LN density in a practical setting is still debatable (16) .
On the other hand, the significance of the diameter of metastatic lesions in LNs and ENI for survival prediction remains to be clarified. Although Mills et al. (12) reported that metastatic lesions in LNs ,0.5 cm in diameter were associated with better clinical outcome, no subsequent studies have validated such an association. Moreover, the conclusions of previous studies that examined the significance of ENI for predicting the survival of patients with bladder cancer were inconsistent. Although three papers from a single center (the University of Bern, Switzerland) have suggested that ENI is the strongest independent prognostic factor for disease-specific survival (DSS) (12 -14) , Kassouf et al. (15) reported that ENI was associated with neither DSS nor RFS.
The aim of this study was to assess the significance of several clinicopathological variables including ENI and the diameter of metastatic lesions for the prediction of outcome in patients with LN metastasis-positive urothelial carcinoma of the urinary bladder after cystectomy.
PATIENTS AND METHODS
We retrospectively reviewed the medical records of 611 consecutive patients who underwent radical cystectomy and pelvic LN dissection for invasive bladder cancer with curative intent at the National Cancer Center Hospital between January 1986 and April 2008. During this period, radical cystectomy was abandoned in 25 patients intraoperatively due to advanced local disease. Patients included in the study were those for whom LN metastases were confirmed histologically in their surgically resected specimens. Patients were excluded if they had received neoadjuvant chemotherapy before surgery, had pure non-urothelial carcinomas histologically (i.e. squamous cell carcinoma and adenocarcinoma), had remote metastases at the time of surgery or had synchronous or metachronous invasive upper urinary tract cancers. On this basis, 46 patients were included in the present study, which comprised 7.5% of the 611 patients who underwent radical cystectomy. This study was approved for analysis by the institutional review board.
All cystectomy specimens were subjected to routine pathological examination. The LN specimen from each anatomical location was separately examined visually and by manual palpation without fat clearing solution, and all macroscopically detected LNs were completely embedded. One hematoxylin-and eosin-stained section was taken per tissue block, and no immunostains were routinely performed. A single pathologist (Y.K.) reviewed the specimens microscopically for this study in a blinded manner. The primary tumors and LNs were staged based on the 2009 UICC TNM system (17) and were evaluated for the diameter of metastatic lesions in the LNs, and the presence or absence of ENI. ENI was defined as obvious disruption of the microscopically visible LN capsule by tumor cells infiltrating into the perinodal tissue (Fig. 1 ).
All patients were followed routinely after surgery every 3 months in the first year, at 3-to 6-month intervals in years 2 -3, every 6 months in years 4 -5 and annually thereafter. Follow-up consisted of physical examination, serum biochemical profile, urine cytology, chest X-ray or computed tomography (CT) imaging of the chest and CT imaging of the abdomen -pelvis.
Survival data were analyzed using the Kaplan -Meier method, and log-rank tests were used to evaluate associations between survival and the variables studied. The duration of follow-up was calculated from the date of surgery to the date of death or last follow-up. Univariate and multivariate Cox proportional hazard models were employed to assess which clinicopathological features were associated with death due to, or recurrence of, bladder cancers. The relationships between the clinicopathological features studied and outcome were summarized in terms of risk ratios and 95% confidence intervals (95% CI). Differences with P values of ,0.05 were considered significant.
RESULTS
The clinicopathological features of the 46 patients included in the study are shown in Table 1 . There were 37 male and 9 female patients, with a median age of 66 (range: 46 -83) years at the time of surgery. The median follow-up duration was 32 (range: 3 -272) months for the patients as a whole and 110.5 (range: 26 -272) months for the 14 patients who were alive at the final follow-up.
Thirty-three patients suffered from disease recurrence, and 28 of them died of metastatic bladder cancer during followup. The 5-year DSS and RFS for the 46 patients overall were 41.3 and 32.2%, respectively (Fig. 2) . The median DSS and RFS were 34 (95% CI: 25 -154) and 11.5 (95% CI: 10 -46) months, respectively (Fig. 2) .
Due to the retrospective nature of this study, the extent of LN dissection was variable; 36 patients underwent limited pelvic lymphadenectomy below the bifurcation of common iliac arteries, whereas 7 and 3 cases up to the level of aortic bifurcation and inferior mesenteric artery, respectively.
Adjuvant systemic chemotherapy was considered for all cases with LN metastasis. However, it was not administered in 28 patients because of impaired performance status and/or high age, or no consent from the patients. The regimens of chemotherapy were two courses of MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) in 16 cases, MEP (methotrexate, etoposide and cisplatin) in 1 and CAP (cyclophosphamide, doxorubicin and cisplatin) in 1.
The results of univariate analysis to examine the contribution of each clinicopathological factor to DSS and RFS are shown in Table 2 . Whereas pT3 -4 tumors did not show significant difference compared with pT2 tumors in terms of DSS and RFS, several LN-related variables were found to be significantly associated with patient prognosis. Therefore, further analyses focused on these LN-related variables. pN status according to the TNM classification, the total number of involved LNs, LN density and ENI were statistically significant variables predictive of DSS, and the total number of involved LNs and LN density were significant variables predictive of RFS. Figure 3 shows DSS of the patients with or without ENI and of the patients with less than five involved LNs or with five or more, analyzed using the Kaplan -Meier method.
Multivariate analysis revealed that the total number of involved LNs, ENI and the diameter of the metastatic lesion 
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were statistically significant variables predictive of DSS (Table 3) . For RFS, the total number of involved LNs was the only variable showing a statistically significant correlation (Table 3) . Thus, ENI, the total number of positive nodes and the diameter of metastatic lesions were independently associated with DSS. Interestingly, the diameter of metastatic lesions was inversely correlated with poorer survival: some patients had a good outcome despite having sizable metastatic nodes. In fact, those with ENI-negative, large (.10 mm) metastatic nodes (seven patients) showed favorable clinical outcome. They showed better DSS and RFS than those with ENI-negative, multiple small metastatic lesions (,10 mm) (eight patients) (P ¼ 0.0156 for DSS and P ¼ 0.0483 for RFS). They also showed better DSS and marginally better RFS than those with ENI-positive nodes (19 patients) (P ¼ 0.0181 for DSS and P ¼ 0.0527 for RFS) (Figs 4 and 5) .
DISCUSSION
The presence of histologically proven LN metastases is an adverse prognostic factor in patients who undergo radical cystectomy for bladder cancer with curative intent. However, the clinical outcome of patients with LN metastases is variable, and several clinicopathological factors have been reported to further stratify the risk of recurrence and death in such patients. In our present study, the number of metastasis-positive nodes was the most significant variable predictive of poor survival. Patients with five or more positive nodes had a significantly worse outcome than those with fewer than five positive nodes (P ¼ 0.0035 for DSS and P ¼ 0.0006 for RFS). Previous studies have also reported similar data using cut-off points of 5, 6 and 8 for the number of LNs in order to discriminate groups with good or poor prognosis (3 -6) .
ENI is reported to represent an aggressive feature of metastatic cancers and to be a significant predictor of poorer outcome in cancers of the kidney, breast, lung, colon, head and neck, penis and ampulla of Vater (18 -24) . Reports examining the significance of ENI in bladder cancer are limited, and their results have been inconsistent. Three papers from a single center (the University of Bern, Switzerland) have suggested that ENI is the strongest independent prognostic factor for DSS (12 -14) . Two other studies reported that ENI was a significant prognostic factor for DSS in univariate analysis, but did not retain its significance in multivariate analysis (6, 25) . A paper from the M.D. Anderson Cancer Center reported that ENI was not associated with DSS (P ¼ 0.43) or RFS (P ¼ 0.82) (15) . Thus, the conclusions have been inconsistent, and the prognostic significance of ENI in bladder cancers is still not fully understood. In the present study, ENI was detected in 19 (41.3%) of 46 node-positive patients, consistent with the reported incidence of ENI of 33 -68% (6,12 -15) , and was associated with poorer prognosis of node-positive patients in both univariate and multivariate analyses.
It was somehow surprising that the diameter of metastatic lesions was inversely associated with poorer DSS. We did experience several patients with sizable nodal metastases who were cured with surgery alone or showed an indolent clinical course after tumor recurrence. LN diameter was significantly larger in ENI-positive cases than in ENI-negative (P ¼ 0.0002, Mann -Whitney's test), and we focused attention on the outliers of this association; seven cases with ENI-negative, large (.10 mm) metastatic nodes. In fact, these seven cases showed favorable DSS, irrespective of the number of metastasis-positive nodes (Fig. 5) . This type of tumors may have limited invasive potential and do not extend beyond the nodal capsule, thus being ENI-negative. In addition, they may have low metastasis potential, and consequently show local proliferation, resulting in a larger metastasis diameter (expansive growth pattern, Fig. 4) . In contrast, patients with ENI-positive nodes (19 patients) had dismal clinical outcome (Fig. 5) . ENI-positive nodes may represent aggressive invasive potential, resulting in the destruction of the LN capsule and invasion into surrounding tissues (infiltrative growth pattern, Fig. 4 ). There was a significant (P , 0.0001) positive correlation between diameter and total number of positive nodes with a Spearman correlation coefficient of 0.5617. Again, we focused attention on the outliers of this association. As shown in the upper panel of Fig. 4 , eight cases had multiple small (,10 mm) LN metastases without ENI. These eight cases also showed poor outcome (Fig. 5) . Multiple small LNs may represent spreading ability of cancer cells via lymphatic vessels before they form large metastatic lesions in LNs (highly spreading pattern, Fig. 4) . Remainders (single small LN metastasis 1070 Lymph node metastasis in bladder cancer without ENI) were in the early phase of either of the three categories (12 patients).
Our data show that the clinical outcome of node-positive patients is not simply stratified according to well-accepted variables, such as the number of positive nodes, that reflect the tumor burden. It is also affected by tumor biology including properties such as invasiveness and metastasis potential, which is reflected in pathological characteristics such as ENI and the diameter of nodal lesions.
In conclusion, the present study has shown that the total number of involved nodes, ENI and the diameter of metastatic lesions are significantly associated with DSS of patients with node-positive urothelial bladder carcinoma. Differences in the characteristics of metastatic nodes such as expansive growth/infiltrative growth/highly spreading pattern would result in the variable clinical outcome. Even the patients with large LN metastases may benefit from meticulous LN dissection if the tumor showed expansive growth pattern.
